Literature DB >> 16098319

Major bleeding complications in a specialized anticoagulation service.

John Fanikos1, Nicole Grasso-Correnti, Ravi Shah, Nils Kucher, Samuel Z Goldhaber.   

Abstract

Major bleeding complications were investigated in 2,460 patients with 3,684 patient-years of warfarin exposure from 2000 to 2003. The most common indications for anticoagulation were atrial fibrillation (30%), venous thromboembolic disease (28%), and mechanical heart valve prosthesis (15%). Eleven patients had 12 nonfatal major bleeding complications, with no fatal bleeds during the study. The incidence of major bleeding complications was 0.12%/year; there were 0.32 bleeds/100 patient-years of coverage. Of the 12 bleeding events, 5 (42%) were intracranial hemorrhages. The average hospitalization cost per patient was dollar 15,988, and the average length of hospitalization was 6.0 days.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098319     DOI: 10.1016/j.amjcard.2005.03.104

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

1.  Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy.

Authors:  Andrea Rubboli; Cecilia Becattini; Freek Wa Verheugt
Journal:  World J Cardiol       Date:  2011-11-26

2.  Fate of newly developed pulmonary embolism after surgery for renal cell carcinoma with vena cava thrombus.

Authors:  Sangjun Yoo; Sang Hoon Song; Heounjeong Go; Dalsan You; Cheryn Song; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn; In Gab Jeong
Journal:  Int Urol Nephrol       Date:  2017-04-11       Impact factor: 2.370

Review 3.  Predicting the risk of venous thromboembolism recurrence.

Authors:  John A Heit
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

4.  Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing.

Authors:  Rosángela Rodríguez-Vélez; Oscar J Ortiz-Rivera; Bruce Bower; Krystyna Gorowski; Andreas Windemuth; David Villagra; Mohan Kocherla; Richard L Seip; Darrin D'Agostino; Cunegundo Vergara; Gualberto Ruaño; Jorge Duconge
Journal:  P R Health Sci J       Date:  2010-12       Impact factor: 0.705

Review 5.  Implementing genotype-guided antithrombotic therapy.

Authors:  Richard L Seip; Jorge Duconge; Gualberto Ruaño
Journal:  Future Cardiol       Date:  2010-05

Review 6.  Understanding the pharmacogenetic approach to warfarin dosing.

Authors:  Ingrid Glurich; James K Burmester; Michael D Caldwell
Journal:  Heart Fail Rev       Date:  2008-11-08       Impact factor: 4.214

7.  Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics.

Authors:  Jonas Wallvik; Anders Själander; Lars Johansson; Orjan Bjuhr; Jan-Håkan Jansson
Journal:  Scand J Prim Health Care       Date:  2007-06       Impact factor: 2.581

8.  Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

Authors:  Andrea L Jorgensen; Sameh Al-Zubiedi; Jieying Eunice Zhang; Andrew Keniry; Anita Hanson; Dyfrig A Hughes; Diane van Eker; Lisa Stevens; Karen Hawkins; Cheng H Toh; Farhad Kamali; Ann K Daly; David Fitzmaurice; Alison Coffey; Paula R Williamson; Brian Kevin Park; Panos Deloukas; Munir Pirmohamed
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

9.  Incidence and predictors of severe bleeding during warfarin treatment.

Authors:  Jonatan D Lindh; Lennart Holm; Marja-Liisa Dahl; Lars Alfredsson; Anders Rane
Journal:  J Thromb Thrombolysis       Date:  2007-05-20       Impact factor: 2.300

10.  Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach.

Authors:  Ali Ali; Claire Bailey; Ahmed H Abdelhafiz
Journal:  Aging Dis       Date:  2012-06-21       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.